培塞利珠单抗治疗对中轴型脊柱关节炎患者前葡萄膜炎发作的影响:C-VIEW 48周中期结果
C-VIEW 是一项正在进行的96周多中心开放标签4期研究,纳入89例有复发性急性前葡萄膜炎病史且疾病活动的中轴型脊柱关节炎患者,接受培塞利珠单抗治疗。48周中期分析显示,治疗期间AAU发生率较治疗前48周降低87%,每患者AAU发生率从1.5降至0.2(p<0.001),未发现新安全性信号。
要点
- 培塞利珠单抗治疗48周使AAU发生率降低87%。
- 每患者AAU发生率从1.5降至0.2(p<0.001)。
- 有复发性AAU病史的活动性axSpA患者可考虑使用培塞利珠单抗。
核心结论
- 培塞利珠单抗治疗48周显著降低活动性axSpA且有复发性AAU病史患者的AAU发作率,提示其是合适治疗选择。
研究设计与样本
- C-VIEW(NCT03020992)为96周正在进行的多中心开放标签4期研究,本次为48周预设中期分析。
- 纳入89例患者,均有axSpA诊断、复发性AAU病史(≥2次发作且入组前1年内≥1次)、HLA-B27阳性、疾病活动且≥2种NSAIDs失败。
- 患者接受培塞利珠单抗400 mg于第0/2/4周,随后200 mg每2周至96周。
- 采用泊松回归比较治疗前48周与治疗期间48周的AAU发作发生率,并考虑患者内相关性。
主要发现
- 89例患者中男性63%,放射学/非放射学axSpA分别为85%/15%,平均axSpA病程8.6年。
- 48周培塞利珠单抗治疗期间,13例(15%)患者发生15次AAU发作。
- AAU发生率从治疗前48周的146.6/100患者年降至治疗期间的18.7/100患者年,降低87%。
- 泊松回归显示每患者AAU发生率从1.5降至0.2(p<0.001)。
- 未发现新的安全性信号。
关键数值与推荐
- 复发性AAU病史定义为≥2次AAU发作且入组前1年内≥1次发作。
- AAU发生率治疗前48周为146.6/100患者年,治疗期间48周为18.7/100患者年。
- 每患者AAU发生率从1.5降至0.2,p<0.001。
临床怎么用
- 对于活动性axSpA且有复发性AAU病史的患者,培塞利珠单抗可显著减少AAU发作。
- 治疗期间需关注AAU发作情况,但本中期分析未发现新安全性信号。
局限性
- 本次为48周预设中期分析,研究尚未完成。
- 研究为开放标签设计,非盲法对照。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Acute anterior uveitis (AAU) is the most common extra-articular manifestation in patients with axial spondyloarthritis (axSpA). C-VIEW investigates the impact of the Fc-free TNF inhibitor certolizumab pegol (CZP) on AAU flares in patients with active axSpA at high risk of recurrent AAU. METHODS: C-VIEW (NCT03020992) is a 96-week ongoing, multicentre, open-label, phase 4 study. Included patients had an axSpA diagnosis, a history of recurrent AAU (≥2 AAU flares, ≥1 flare in the year prior to study entry), HLA-B27 positivity, active disease, and failure of ≥2 non-steroidal anti-inflammatory drugs. Patients received CZP 400 mg at Weeks 0/2/4, then 200 mg every 2 weeks up to 96 weeks. This 48-week pre-planned interim analysis compares AAU flare incidence in the 48 weeks before and after initiation of CZP treatment, using Poisson regression to account for possible within-patient correlations. RESULTS: In total, 89 patients were included (male: 63%; radiographic/non-radiographic axSpA: 85%/15%; mean axSpA disease duration: 8.6 years). During 48 weeks' CZP treatment, 13 (15%) patients experienced 15 AAU flares, representing an 87% reduction in AAU incidence rate (146.6 per 100 patient-years (PY) in the 48 weeks pre-baseline to 18.7 per 100 PY during CZP treatment). Poisson regression analysis showed that the incidence rate of AAU per patient reduced from 1.5 to 0.2 (p<0.001). No new safety signals were identified. CONCLUSIONS: There was a significant reduction in the AAU flare rate during 48 weeks of CZP treatment, indicating that CZP is a suitable treatment option for patients with active axSpA and a history of recurrent AAU.
引用
- van der Horst-Bruinsma I, van Bentum R, Verbraak FD, et al. The impact of certolizumab pegol treatment on the incidence of anterior uveitis flares in patients with axial spondyloarthritis: 48-week interim results from C-VIEW. RMD Open. 2020. PMID: 32371433. doi:10.1136/rmdopen-2019-001161
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。